Lars Kober

Professor Lars Kober is a Visiting Professor at the School of Cardiovascular & Metabolic Health, specializing in heart failure, renal-cardiac interactions, and clinical pharmacology. His work focuses on advancing therapeutic strategies for heart failure (HF) patients, particularly through large-scale clinical trials like DAPA-HF and PARADIGM-HF. He has contributed to understanding the efficacy of SGLT2 inhibitors (e.g., dapagliflozin), mineralocorticoid antagonists, and angiotensin receptor-neprilysin inhibitors in HF management. His research spans epidemiological studies, drug efficacy analysis, and patient-centered outcomes, including quality of life metrics and mortality prediction. Kober has authored over 120 peer-reviewed articles, emphasizing real-world data and translational research.

Key Contributions:

• Co-developed ESC Guidelines for acute and chronic heart failure (2012).
• Leading investigator in the PARADISE-MI trial evaluating sacubitril/valsartan post-myocardial infarction.
• Explored sex differences in cardiac outcomes post-MI and the obesity paradox in HF.

Research Interests:

• Pharmacological management of HF across ejection fraction spectrums.
• Renal dysfunction in HF and its prognostic implications.
• Role of biomarkers (e.g., NT-proBNP, IL-6) in guiding therapy.

Grants & Collaborations:

• Recipient of grants for multinational HF trials (e.g., DELIVER, MIRACLE).
• Collaborates with global institutions on pragmatic clinical trials (PRIME-9 network).